Journey Medical (NASDAQ:DERM) and Oculis (NASDAQ:OCS) Financial Analysis.

Oculis ( NASDAQ:OCS – Get Your Free Report ) and Journey Medical ( NASDAQ:DERM – Get Your Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Analyst recommendations

This is a summary of current recommendations for Oculis and Journey Medical, as reported by MarketBeat.com.

Oculis currently has a consensus target price of $30.17, suggesting a potential upside of 149.11%. Journey Medical has a consensus price target of $9.38, suggesting a potential upside of 80.29%. Given Oculis’ higher probable upside, research analysts plainly believe Oculis is more favorable than Journey Medical.

Rating and Earnings

This table compares Oculis and Journey Medical’s gross revenue, earnings per share (EPS) and valuation.

Journey Medical has higher revenue and earnings than Oculis. Journey Medical is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

return

This table compares Oculis and Journey Medical’s net margins, return on equity and return on assets.

Volatility and risk

Oculis has a beta of 0.3, suggesting its share price is 70% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.9, suggesting its share price is 10% less volatile than the S&P 500. less volatile than the S&P 500.

Institutional and insider ownership

22.3% of Oculis shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 19.4% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that big money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Journey Medical beats Oculis on 10 of the 15 factors compared between the two stocks.

About Oculis

(Get a free report)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of eye diseases. The Company’s lead product candidate is OCS-01, a topical optireach formulation of dexamethasone, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a lead biologic candidate in Phase 2b clinical trials for the treatment of dry eye disease; and OCS-05, a disease-modifying neuroprotective agent for neurological injury with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

About Journey Medical

(Get a free report)

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towel for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin medication for treating severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of moderate to severe inflammatory lesions of non-nodular acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory rosacea lesions; Exelderm cream and solution, an antifungal intended for local use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scratches; dermal ulcers; donor sites; first and second degree burns, including sunburn; and radiation dermatitis. In addition, the company markets the cream and solution with sulconazole nitrate indicated for the treatment of tinea cruris, tinea corporis and tinea versicolor; and doxycycline hyclate tablets as adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was founded in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Get news and reviews for Oculis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Oculis and related companies with MarketBeat.com’s FREE daily email newsletter.